ZIA CP010206-10544 (ZIA) | |||
---|---|---|---|
Title | The New Mexico Pap Registry | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Schiffman, Mark | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $10,792 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Cervical Cancer (100.0%) | ||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
"The goals of The New Mexico HPV Pap Registry, on which Dr. Schiffman and Dr. Gage serve as collaborators, are: Implement and maintain a state-wide woman-based information system developed and housed at the University of New Mexico, House of Prevention Epidemiology (HOPE) that can compile complete cervical cancer screening and diagnostic histories. Characterize cervical cancer screening patterns, diagnostic and treatment services, outcomes and practices, and cost-effectiveness by selected characteristics including race/ethnicity, age and state geographic location. Examine prophylactic HPV vaccine efficacy, effectiveness and safety in preventing precancerous conditions using the woman-based New Mexico HPV Pap Registry and the New Mexico state-wide immunization information system (NM-SIIS). In the future, the New Mexico SEER Tumor Registry can be used as part of these assessments to evaluate the impact on cancer. Enable research projects under IRB approval. Pursuant to review by the HPV Pap Registry Steering Committee and appropriate human subject review committees (see section II below), Registry information that is stripped of personal identifiers (de-identified) can be linked to clinical information under an honest broker policy for large population-based studies critical to evaluating the delivery of cervical cancer prevention and therapeutic strategies in New Mexico. HPV type-specific determinations pre- and post-vaccine will be made in population-based samples of women with normal cytology and with HPV-related cervical abnormalities to examine viral ecology and effectiveness of the vaccine over time. Dr. Schiffman is on the Steering Committtee of the registry but is resigning as of summer 2015. " |